Author: Sunny Dhillon BPharm, MBA
Absorption is the defining determinant of whether a nutrient or therapeutic compound exerts any meaningful physiological effect. Across delivery platforms, bioavailability varies widely because each route encounters distinct anatomical and biochemical barriers that limit systemic uptake.1,2 Oral thin films (OTFs) have emerged as a modern dosage form specifically designed to overcome many of these limitations by enabling rapid dissolution, pre‑gastric absorption, and partial avoidance of first‑pass metabolism.3,4
Traditional oral dosage forms — including tablets, capsules, and gummies — must transit the gastrointestinal tract, where acidic pH, digestive enzymes, poor solubility, and hepatic first‑pass metabolism significantly reduce the fraction of a dose that reaches systemic circulation.5,6 These limitations disproportionately affect peptides, polyphenols, fat‑soluble vitamins, and botanicals with low aqueous solubility, resulting in minimal systemic exposure despite high labelled doses.7
In contrast, OTFs dissolve rapidly upon contact with saliva, releasing actives directly onto the highly vascularised buccal and sublingual mucosa.8 This route provides a thin epithelial barrier, rich blood supply, and the potential to bypass hepatic first‑pass metabolism, supporting faster onset and higher effective bioavailability for suitable molecules.9,10
Collectively, the literature positions OTFs as a patient‑centric, biopharmaceutically advantageous platform capable of delivering improved absorption efficiency relative to conventional oral dosage forms.11
Mechanistic Barriers to Absorption Across Delivery Platforms — and How OTFs Address Them
Gastrointestinal Delivery (Tablets, Capsules, Powders)
Conventional oral dosage forms must survive gastric acidity, enzymatic degradation, and variable intestinal transit times.12 Many compounds — particularly peptides, polyphenols, and lipophilic molecules — exhibit poor permeability across the intestinal epithelium and undergo extensive first‑pass metabolism.13 These factors collectively reduce bioavailability and often necessitate higher doses.
Gummy and Chewable Formats
Gummies improve adherence but remain subject to the same gastrointestinal and first‑pass barriers as tablets. Their polymeric matrices and heat‑based manufacturing can degrade heat‑sensitive vitamins and limit payload capacity.14,15 As a result, systemic uptake of complex or fragile molecules remains low.
Liposomal and Nanoemulsion Systems
Liposomal encapsulation enhances solubility and protects actives from degradation, improving membrane permeability.16 Liposomal formulations can increase bioavailability of curcumin, glutathione, and fat‑soluble vitamins by several‑fold compared with standard oral forms.17 However, liposome stability and oxidation remain formulation challenges.18
Buccal and Sublingual Delivery (Oral Thin Films, Sprays)
OTFs dissolve rapidly in the oral cavity, enabling immediate drug release and exposure to the buccal and sublingual mucosa.19 This route provides:
-
rapid onset due to fast dissolution
-
enhanced absorption through a highly vascularised surface
-
partial avoidance of first‑pass metabolism
-
improved bioavailability for suitable molecules
OTFs can also incorporate permeation enhancers, solubilising agents, and mucoadhesive polymers, which increase mucosal residence time and improve transmucosal flux.20,21 These formulation strategies further support superior absorption profiles compared with traditional solid oral dosage forms.
Transdermal Delivery (Patches, Gels)
Transdermal systems avoid gastrointestinal degradation and hepatic first-pass metabolism but are constrained by the stratum corneum, which restricts permeation to molecules under ~500 Da with high lipophilicity.22 This makes the route suitable for hormones and nicotine but unsuitable for most botanicals, minerals, and peptides.23
Why Oral Thin Films Offer a Distinct Absorption Advantage
Across delivery platforms, OTFs uniquely combine rapid disintegration, pre‑gastric absorption, high mucosal permeability, and formulation flexibility. The literature consistently highlights several key benefits:
-
Rapid onset: OTFs disintegrate within seconds, enabling immediate release and absorption.24
-
Enhanced bioavailability: Pre‑gastric uptake and reduced first‑pass metabolism improve systemic exposure for suitable molecules.25
-
Improved permeability: Penetration enhancers and mucoadhesive polymers increase transmucosal flux.26
-
Patient‑centric design: OTFs are discreet, water‑free, and suitable for populations with swallowing difficulties.27
-
GMP‑aligned uniformity: Thin‑film matrices allow precise dose distribution when manufactured under appropriate controls.28
These advantages position OTFs as a modern, clinically relevant dosage form capable of delivering superior absorption efficiency relative to tablets, capsules, and gummies — particularly for molecules with poor gastrointestinal uptake.
Conclusion
Absorption is the primary determinant of real‑world efficacy across all delivery platforms. Oral thin films offer a scientifically validated solution to many of the barriers that limit bioavailability in traditional oral dosage forms. Through rapid dissolution, mucosal absorption, and partial avoidance of first‑pass metabolism, OTFs provide a patient‑friendly and biopharmaceutically advantageous route capable of delivering faster onset and improved systemic exposure for appropriately selected molecules.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider before beginning any supplement regimen.
References
-
Shargel, L., & Yu, A. (2016). Applied Biopharmaceutics & Pharmacokinetics.
-
Pang, K. S. (2003). First‑pass metabolism. J Clin Pharmacol, 43(6), 581–598.
-
Kunte, S., & Tandale, P. (2010). Fast dissolving strips. Int J Pharm Sci Rev Res, 4(2), 9–15.
-
Borges, A. F., et al. (2015). Oral films: Current status. J Control Release, 206, 1–19.
-
Dressman, J., & Reppas, C. (2000). GI absorption. Eur J Pharm Sci, 11, S73–S80.
-
Lennernäs, H. (1998). Intestinal permeability. Clin Pharmacokinet, 36(1), 1–30.
-
Manach, C., et al. (2005). Polyphenol bioavailability. Am J Clin Nutr, 81, 230S–242S.
-
Paul, S., et al. (2023). Advances in oral thin films. J Drug Deliv Sci Tech, 80, 104–112.
-
Shojaei, A. (1998). Buccal mucosa absorption. J Pharm Pharm Sci, 1(1), 15–30.
-
Siddiqui, N., et al. (2022). Fast dissolving systems. Int J Pharm Sci Res, 13(3), 1000–1012.
-
Irfan, M., et al. (2015). Orally disintegrating films. Saudi Pharm J, 24(5), 537–546.
-
Ball, G. (2006). Vitamins in Foods. CRC Press.
-
O’Brien, C., et al. (2022). Vitamin stability in gummies. Food Chem, 380, 132–140.
-
Sari, T., et al. (2015). Liposomal curcumin. Food Res Int, 74, 170–178.
-
Mantovani, G., et al. (2020). Liposomal glutathione. Eur J Pharm Sci, 150, 105–112.
-
Torchilin, V. (2005). Liposomes. Nat Rev Drug Discov, 4(2), 145–160.
-
Cilurzo, F., et al. (2011). Maltodextrin films. Eur J Pharm Biopharm, 78(2), 395–403.
-
Bos, J., & Meinardi, M. (2000). 500 Dalton rule. Exp Dermatol, 9(3), 165–169.
-
Prausnitz, M., & Langer, R. (2008). Transdermal delivery. Nat Biotechnol, 26(11), 1261–1268.
-
Mahajan, A., et al. (2018). Fast dissolving films. Int J Pharm Sci Rev Res, 52(1), 35–44.
-
IJIRG1402115. (2015). Fast‑dissolving oral film review. Int J Innovative Res Group.
-
ODF Reference (2025). Oral dissolving film technology: Mechanistic and formulation considerations.
-
International Journal of Novel Research and Development. (2023). Mouth dissolving films. IJNRD, 8(5), 120–130.
